SK bioscience received A+ in Social and A in Environment and Governance categories in the first ESG evaluation from the KCGS

SK bioscience is recognized for efforts to create social and economic values through the Korea’s first COVID-19 vaccine development

SK bioscience announced that the company has obtained A+ grade in social category and A grade in environment and governance categories in recognition of its efforts, such as creating social value through the development of the Korea’s first COVID-19 vaccine, SKYCovione and publishing the first ESG report in this year.

In particular, this is the first year that KCGS raised the difficulty of evaluation standards in all categories of environment, society, and governance by reflecting recent global ESG trends. SK bioscience achieved the result in recognition of its efforts in creating social and economic values and advancing the management system.

SK bioscience received positive reviews in areas such as improving human health through vaccine development, pursuing happiness of stakeholders and complying with strict global regulations in the process of vaccine development. In addition, SK bioscience was highly evaluated that it contributed to solving social problems through various local social contribution activities and established a sustainable management system by disclosing ESG management information through ESG reports and the foundation for the board of directors-centered management.

SK bioscience will continuously achieve in the field of environment, such as enhancement of the environmental management system, and responding to climate change through the realization of Net Zero. In the field of society, SK will achieve expanding human resources/human rights management, creation of social value (SV) in the local community, creation of SV through business, and establishment of a global bio ecosystem. In the field of governance structure, SK bioscience will establish ESG management internalization and board-centered management, strengthening as 8 strategic goal plans.

In line with the advanced global ESG management environment, SK bioscience acquired ISO14001, an international environmental management system certification for L HOUSE, a vaccine production facility of SK bioscience this month, and completed the establishment of a human rights management declaration to pursue the continuous happiness of members and stakeholders.

SK bioscience plans to establish a climate change response strategy and carbon neutral roadmap and publish a Taskforce on Climate-related Financial Disclosures (TCFD) report within the year. SK bioscience will also conduct human rights impact assessments, establish codes of conduct for suppliers, supply chain ESG management strategies and systems.

Jaeyong Ahn, CEO of SK bioscience said, “The results of this evaluation were able to be achieved by the efforts of all members and stakeholders to fulfill their duties in the two areas, such as human health promotion and social responsibility. We will continue to achieve sustainable growth not just for ourselves, but for the entire society,”